GoodRx price target lowered to $6 from $7 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on GoodRx (GDRX) to $6 from $7 and keeps an Equal Weight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group. Among Healthcare Technology and Providers, the firm remains selective due to mixed demand and policy uncertainties, the analyst added.